Form 4: Marimed CEO Jon R. Levine Reports Routine Stock Vesting and Tax-Related Share Disposition

Marimed Inc.'s President and CEO, Jon R. Levine, reported the vesting of Restricted Stock Units (RSUs) into common stock and a subsequent disposition of shares to cover tax withholding obligations.

Summary

• Jon R. Levine, President and CEO, Director, and 10% Owner of Marimed Inc. (MRMD), reported transactions on June 15, 2025.
• Mr. Levine acquired 89,859 shares of common stock through the conversion of Restricted Stock Units (RSUs) on a one-for-one basis, with a transaction price of $0.
• Concurrently, 31,137 shares of common stock were disposed of to satisfy tax withholding obligations related to the RSU vesting, at a price of $0.0725 per share.
• Following these transactions, Mr. Levine directly beneficially owns 20,767,263 shares of common stock.
• Additionally, 6,684,640 shares are indirectly held by the Jon Levine Family Trust, for which Mr. Levine disclaims beneficial ownership.
• The remaining 179,719 Restricted Stock Units (RSUs) are scheduled to vest in two equal installments on September 15, 2025, and December 15, 2025.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it reflects the vesting of executive compensation, indicating continued alignment of management's interests with shareholders. The share disposition for tax purposes is a neutral, routine event.

Positives

• The vesting of 89,859 Restricted Stock Units (RSUs) indicates the achievement of performance or time-based criteria, converting into direct common stock ownership for the CEO.
• The conversion of RSUs at a $0 price reflects a non-cash compensation event, increasing the CEO's direct equity stake in the company.

Negatives

• A portion of the vested shares (31,137) was disposed of to cover tax withholding obligations, resulting in a slight reduction in the CEO's direct beneficial ownership post-vesting.

Risks

• No specific new risks related to the company's operations or financial health were disclosed in this routine insider transaction filing.

Future Outlook

The document indicates that the remaining 179,719 Restricted Stock Units (RSUs) held by Jon R. Levine are scheduled to vest in two equal installments on September 15, 2025, and December 15, 2025, in accordance with the terms of his award agreement.

Management Comments

• The filing was signed by Jon R. Levine, President and CEO of Marimed Inc., on June 16, 2025.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically the vesting of equity compensation and subsequent tax-related share disposition. Such filings are standard practice for publicly traded companies and their executives, providing transparency into changes in beneficial ownership.

Comparison to Industry Standards

• This document is a routine insider transaction report (Form 4) and does not contain financial performance results or operational metrics that would typically be compared to global benchmarks or specific comparable companies/projects. Its purpose is to disclose changes in beneficial ownership by an insider.

Related Party Transactions

• The filing notes that 6,684,640 shares of common stock are held indirectly by the Jon Levine Family Trust, for which the Reporting Person disclaims beneficial ownership. This is a pre-existing indirect holding, not a new transaction.

Stakeholder Impact

• Shareholders: The report provides transparency regarding changes in the CEO's direct and indirect ownership, which is a routine aspect of executive compensation and insider holdings.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• Remaining Restricted Stock Units (RSUs) held by Jon R. Levine are scheduled to vest in two equal installments on September 15, 2025, and December 15, 2025.

Key Dates

Keywords

Marimed Inc., MRMD, Jon R. Levine, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Common Stock, Beneficial Ownership, CEO, Director, Tax Withholding